nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—CYP3A4—Bexarotene—hematologic cancer	0.0503	0.0829	CbGbCtD
Avanafil—CYP3A4—Lomustine—hematologic cancer	0.0467	0.0771	CbGbCtD
Avanafil—CYP3A4—Busulfan—hematologic cancer	0.0467	0.0771	CbGbCtD
Avanafil—CYP3A4—Thiotepa—hematologic cancer	0.0416	0.0687	CbGbCtD
Avanafil—CYP3A4—Methoxsalen—hematologic cancer	0.0324	0.0534	CbGbCtD
Avanafil—CYP3A4—Bortezomib—hematologic cancer	0.0308	0.0508	CbGbCtD
Avanafil—CYP3A4—Daunorubicin—hematologic cancer	0.0295	0.0486	CbGbCtD
Avanafil—CYP3A4—Cytarabine—hematologic cancer	0.026	0.0429	CbGbCtD
Avanafil—CYP3A4—Teniposide—hematologic cancer	0.0256	0.0422	CbGbCtD
Avanafil—CYP3A4—Ifosfamide—hematologic cancer	0.0236	0.039	CbGbCtD
Avanafil—CYP3A4—Imatinib—hematologic cancer	0.0226	0.0372	CbGbCtD
Avanafil—CYP3A4—Ruxolitinib—hematologic cancer	0.0213	0.0351	CbGbCtD
Avanafil—CYP3A4—Nilotinib—hematologic cancer	0.0205	0.0338	CbGbCtD
Avanafil—CYP3A4—Vinorelbine—hematologic cancer	0.0203	0.0335	CbGbCtD
Avanafil—CYP3A4—Triamcinolone—hematologic cancer	0.0186	0.0307	CbGbCtD
Avanafil—CYP3A4—Dasatinib—hematologic cancer	0.0181	0.0299	CbGbCtD
Avanafil—CYP3A4—Mitoxantrone—hematologic cancer	0.0179	0.0295	CbGbCtD
Avanafil—CYP3A4—Betamethasone—hematologic cancer	0.016	0.0263	CbGbCtD
Avanafil—CYP3A4—Prednisolone—hematologic cancer	0.0157	0.026	CbGbCtD
Avanafil—CYP3A4—Prednisone—hematologic cancer	0.0149	0.0245	CbGbCtD
Avanafil—CYP3A4—Irinotecan—hematologic cancer	0.0141	0.0233	CbGbCtD
Avanafil—CYP3A4—Vinblastine—hematologic cancer	0.0125	0.0207	CbGbCtD
Avanafil—CYP3A4—Vincristine—hematologic cancer	0.0123	0.0203	CbGbCtD
Avanafil—CYP3A4—Etoposide—hematologic cancer	0.0113	0.0186	CbGbCtD
Avanafil—CYP3A4—Dexamethasone—hematologic cancer	0.00928	0.0153	CbGbCtD
Avanafil—CYP3A4—Doxorubicin—hematologic cancer	0.0077	0.0127	CbGbCtD
Avanafil—PDE5A—hematopoietic system—hematologic cancer	0.00156	0.224	CbGeAlD
Avanafil—PDE5A—gonad—hematologic cancer	0.00118	0.17	CbGeAlD
Avanafil—PDE5A—blood—hematologic cancer	0.00103	0.148	CbGeAlD
Avanafil—PDE5A—lung—hematologic cancer	0.000904	0.13	CbGeAlD
Avanafil—PDE5A—testis—hematologic cancer	0.000853	0.123	CbGeAlD
Avanafil—PDE5A—lymph node—hematologic cancer	0.000618	0.0889	CbGeAlD
Avanafil—CYP3A4—hematopoietic system—hematologic cancer	0.000485	0.0698	CbGeAlD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—EPHX1—hematologic cancer	0.000329	0.044	CbGpPWpGaD
Avanafil—CYP3A4—blood—hematologic cancer	0.000321	0.0462	CbGeAlD
Avanafil—PDE5A—Platelet homeostasis—FGR—hematologic cancer	0.000315	0.0421	CbGpPWpGaD
Avanafil—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—hematologic cancer	0.000269	0.0359	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—EHD3—hematologic cancer	0.000234	0.0312	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SPN—hematologic cancer	0.000199	0.0266	CbGpPWpGaD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—ABCC3—hematologic cancer	0.000191	0.0255	CbGpPWpGaD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—UGT1A1—hematologic cancer	0.000179	0.0239	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CD2—hematologic cancer	0.000177	0.0237	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CD58—hematologic cancer	0.000151	0.0201	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—THPO—hematologic cancer	0.000151	0.0201	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SRGN—hematologic cancer	0.000134	0.0179	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—MAPK14—hematologic cancer	0.00013	0.0174	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—MPL—hematologic cancer	0.000128	0.0171	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—S100A10—hematologic cancer	0.000123	0.0164	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—PTPN11—hematologic cancer	0.000118	0.0158	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—GATA2—hematologic cancer	0.000118	0.0158	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—UGT1A1—hematologic cancer	0.000115	0.0153	CbGpPWpGaD
Avanafil—CYP3A4—Farnesoid X Receptor  Pathway—NR0B2—hematologic cancer	0.000112	0.015	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ATP1B1—hematologic cancer	0.000107	0.0143	CbGpPWpGaD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—GSTM1—hematologic cancer	0.000105	0.014	CbGpPWpGaD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC3—hematologic cancer	0.000104	0.0139	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—GATA1—hematologic cancer	0.000102	0.0136	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—ABCG2—hematologic cancer	9.93e-05	0.0133	CbGpPWpGaD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—ABCB1—hematologic cancer	9.7e-05	0.0129	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—UGT1A1—hematologic cancer	9.37e-05	0.0125	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ANXA2—hematologic cancer	9.32e-05	0.0124	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—GNA13—hematologic cancer	8.66e-05	0.0116	CbGpPWpGaD
Avanafil—CYP3A4—Farnesoid X Receptor  Pathway—FGF19—hematologic cancer	8.44e-05	0.0113	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—JAK3—hematologic cancer	8.26e-05	0.011	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ITGAX—hematologic cancer	8.26e-05	0.011	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CD9—hematologic cancer	8.14e-05	0.0109	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—F3—hematologic cancer	8.14e-05	0.0109	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SELL—hematologic cancer	7.92e-05	0.0106	CbGpPWpGaD
Avanafil—Headache—Alitretinoin—hematologic cancer	7.85e-05	0.000207	CcSEcCtD
Avanafil—Diarrhoea—Gemcitabine—hematologic cancer	7.83e-05	0.000207	CcSEcCtD
Avanafil—Nausea—Thalidomide—hematologic cancer	7.82e-05	0.000206	CcSEcCtD
Avanafil—Dyspepsia—Triamcinolone—hematologic cancer	7.8e-05	0.000206	CcSEcCtD
Avanafil—Rash—Ifosfamide—hematologic cancer	7.8e-05	0.000206	CcSEcCtD
Avanafil—Dermatitis—Ifosfamide—hematologic cancer	7.8e-05	0.000206	CcSEcCtD
Avanafil—Dizziness—Irinotecan—hematologic cancer	7.77e-05	0.000205	CcSEcCtD
Avanafil—Body temperature increased—Etoposide—hematologic cancer	7.73e-05	0.000204	CcSEcCtD
Avanafil—Urinary tract infection—Doxorubicin—hematologic cancer	7.73e-05	0.000204	CcSEcCtD
Avanafil—PDE5A—Hemostasis—IL3RA—hematologic cancer	7.72e-05	0.0103	CbGpPWpGaD
Avanafil—Vertigo—Prednisone—hematologic cancer	7.71e-05	0.000203	CcSEcCtD
Avanafil—Eye disorder—Methotrexate—hematologic cancer	7.7e-05	0.000203	CcSEcCtD
Avanafil—Vomiting—Vincristine—hematologic cancer	7.67e-05	0.000202	CcSEcCtD
Avanafil—Asthenia—Cisplatin—hematologic cancer	7.66e-05	0.000202	CcSEcCtD
Avanafil—Cardiac disorder—Methotrexate—hematologic cancer	7.65e-05	0.000202	CcSEcCtD
Avanafil—Fatigue—Triamcinolone—hematologic cancer	7.64e-05	0.000202	CcSEcCtD
Avanafil—Urinary tract disorder—Epirubicin—hematologic cancer	7.62e-05	0.000201	CcSEcCtD
Avanafil—Rash—Vincristine—hematologic cancer	7.61e-05	0.000201	CcSEcCtD
Avanafil—Dermatitis—Vincristine—hematologic cancer	7.6e-05	0.0002	CcSEcCtD
Avanafil—Oedema peripheral—Epirubicin—hematologic cancer	7.6e-05	0.0002	CcSEcCtD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—hematologic cancer	7.58e-05	0.0101	CbGpPWpGaD
Avanafil—Haematuria—Doxorubicin—hematologic cancer	7.58e-05	0.0002	CcSEcCtD
Avanafil—Connective tissue disorder—Epirubicin—hematologic cancer	7.58e-05	0.0002	CcSEcCtD
Avanafil—Urethral disorder—Epirubicin—hematologic cancer	7.56e-05	0.000199	CcSEcCtD
Avanafil—Headache—Vincristine—hematologic cancer	7.56e-05	0.000199	CcSEcCtD
Avanafil—Hypotension—Betamethasone—hematologic cancer	7.52e-05	0.000198	CcSEcCtD
Avanafil—Hypotension—Dexamethasone—hematologic cancer	7.52e-05	0.000198	CcSEcCtD
Avanafil—Nausea—Carmustine—hematologic cancer	7.51e-05	0.000198	CcSEcCtD
Avanafil—Epistaxis—Doxorubicin—hematologic cancer	7.5e-05	0.000198	CcSEcCtD
Avanafil—Angiopathy—Methotrexate—hematologic cancer	7.48e-05	0.000197	CcSEcCtD
Avanafil—Vomiting—Irinotecan—hematologic cancer	7.47e-05	0.000197	CcSEcCtD
Avanafil—Vomiting—Mitoxantrone—hematologic cancer	7.47e-05	0.000197	CcSEcCtD
Avanafil—Sinusitis—Doxorubicin—hematologic cancer	7.46e-05	0.000197	CcSEcCtD
Avanafil—Immune system disorder—Methotrexate—hematologic cancer	7.44e-05	0.000196	CcSEcCtD
Avanafil—Nausea—Alitretinoin—hematologic cancer	7.44e-05	0.000196	CcSEcCtD
Avanafil—Mediastinal disorder—Methotrexate—hematologic cancer	7.43e-05	0.000196	CcSEcCtD
Avanafil—Hypertension—Prednisone—hematologic cancer	7.41e-05	0.000195	CcSEcCtD
Avanafil—Rash—Mitoxantrone—hematologic cancer	7.41e-05	0.000195	CcSEcCtD
Avanafil—Rash—Irinotecan—hematologic cancer	7.41e-05	0.000195	CcSEcCtD
Avanafil—Dermatitis—Mitoxantrone—hematologic cancer	7.4e-05	0.000195	CcSEcCtD
Avanafil—Dermatitis—Irinotecan—hematologic cancer	7.4e-05	0.000195	CcSEcCtD
Avanafil—Headache—Mitoxantrone—hematologic cancer	7.36e-05	0.000194	CcSEcCtD
Avanafil—Headache—Irinotecan—hematologic cancer	7.36e-05	0.000194	CcSEcCtD
Avanafil—Nausea—Ifosfamide—hematologic cancer	7.35e-05	0.000194	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Betamethasone—hematologic cancer	7.33e-05	0.000193	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	7.33e-05	0.000193	CcSEcCtD
Avanafil—Arthralgia—Prednisone—hematologic cancer	7.31e-05	0.000193	CcSEcCtD
Avanafil—Myalgia—Prednisone—hematologic cancer	7.31e-05	0.000193	CcSEcCtD
Avanafil—Diarrhoea—Cisplatin—hematologic cancer	7.3e-05	0.000193	CcSEcCtD
Avanafil—Vomiting—Gemcitabine—hematologic cancer	7.28e-05	0.000192	CcSEcCtD
Avanafil—Insomnia—Betamethasone—hematologic cancer	7.28e-05	0.000192	CcSEcCtD
Avanafil—Insomnia—Dexamethasone—hematologic cancer	7.28e-05	0.000192	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	7.26e-05	0.000191	CcSEcCtD
Avanafil—Mental disorder—Methotrexate—hematologic cancer	7.22e-05	0.00019	CcSEcCtD
Avanafil—Rash—Gemcitabine—hematologic cancer	7.22e-05	0.00019	CcSEcCtD
Avanafil—Dermatitis—Gemcitabine—hematologic cancer	7.21e-05	0.00019	CcSEcCtD
Avanafil—Eye disorder—Epirubicin—hematologic cancer	7.21e-05	0.00019	CcSEcCtD
Avanafil—Malnutrition—Methotrexate—hematologic cancer	7.17e-05	0.000189	CcSEcCtD
Avanafil—Headache—Gemcitabine—hematologic cancer	7.17e-05	0.000189	CcSEcCtD
Avanafil—Nausea—Vincristine—hematologic cancer	7.17e-05	0.000189	CcSEcCtD
Avanafil—Flushing—Epirubicin—hematologic cancer	7.16e-05	0.000189	CcSEcCtD
Avanafil—Cardiac disorder—Epirubicin—hematologic cancer	7.16e-05	0.000189	CcSEcCtD
Avanafil—Dyspepsia—Betamethasone—hematologic cancer	7.08e-05	0.000187	CcSEcCtD
Avanafil—Dyspepsia—Dexamethasone—hematologic cancer	7.08e-05	0.000187	CcSEcCtD
Avanafil—PDE5A—Hemostasis—FGR—hematologic cancer	7.06e-05	0.00943	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—H3F3B—hematologic cancer	7.06e-05	0.00943	CbGpPWpGaD
Avanafil—Urinary tract disorder—Doxorubicin—hematologic cancer	7.05e-05	0.000186	CcSEcCtD
Avanafil—Oedema peripheral—Doxorubicin—hematologic cancer	7.03e-05	0.000185	CcSEcCtD
Avanafil—Asthenia—Etoposide—hematologic cancer	7.01e-05	0.000185	CcSEcCtD
Avanafil—Connective tissue disorder—Doxorubicin—hematologic cancer	7.01e-05	0.000185	CcSEcCtD
Avanafil—Body temperature increased—Triamcinolone—hematologic cancer	7.01e-05	0.000185	CcSEcCtD
Avanafil—Angiopathy—Epirubicin—hematologic cancer	7e-05	0.000185	CcSEcCtD
Avanafil—Urethral disorder—Doxorubicin—hematologic cancer	7e-05	0.000184	CcSEcCtD
Avanafil—Nausea—Mitoxantrone—hematologic cancer	6.98e-05	0.000184	CcSEcCtD
Avanafil—Nausea—Irinotecan—hematologic cancer	6.98e-05	0.000184	CcSEcCtD
Avanafil—Immune system disorder—Epirubicin—hematologic cancer	6.97e-05	0.000184	CcSEcCtD
Avanafil—Infection—Prednisone—hematologic cancer	6.96e-05	0.000184	CcSEcCtD
Avanafil—Mediastinal disorder—Epirubicin—hematologic cancer	6.95e-05	0.000183	CcSEcCtD
Avanafil—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.95e-05	0.000183	CcSEcCtD
Avanafil—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.95e-05	0.000183	CcSEcCtD
Avanafil—Back pain—Methotrexate—hematologic cancer	6.94e-05	0.000183	CcSEcCtD
Avanafil—Fatigue—Betamethasone—hematologic cancer	6.94e-05	0.000183	CcSEcCtD
Avanafil—Fatigue—Dexamethasone—hematologic cancer	6.94e-05	0.000183	CcSEcCtD
Avanafil—Pruritus—Etoposide—hematologic cancer	6.92e-05	0.000182	CcSEcCtD
Avanafil—Nervous system disorder—Prednisone—hematologic cancer	6.87e-05	0.000181	CcSEcCtD
Avanafil—Tachycardia—Prednisone—hematologic cancer	6.84e-05	0.00018	CcSEcCtD
Avanafil—Skin disorder—Prednisone—hematologic cancer	6.81e-05	0.000179	CcSEcCtD
Avanafil—Nausea—Gemcitabine—hematologic cancer	6.8e-05	0.000179	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ITGAL—hematologic cancer	6.8e-05	0.00907	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—MYB—hematologic cancer	6.8e-05	0.00907	CbGpPWpGaD
Avanafil—Vomiting—Cisplatin—hematologic cancer	6.78e-05	0.000179	CcSEcCtD
Avanafil—Vision blurred—Methotrexate—hematologic cancer	6.76e-05	0.000178	CcSEcCtD
Avanafil—Mental disorder—Epirubicin—hematologic cancer	6.76e-05	0.000178	CcSEcCtD
Avanafil—Rash—Cisplatin—hematologic cancer	6.73e-05	0.000177	CcSEcCtD
Avanafil—Dermatitis—Cisplatin—hematologic cancer	6.72e-05	0.000177	CcSEcCtD
Avanafil—Malnutrition—Epirubicin—hematologic cancer	6.71e-05	0.000177	CcSEcCtD
Avanafil—Diarrhoea—Etoposide—hematologic cancer	6.69e-05	0.000176	CcSEcCtD
Avanafil—Eye disorder—Doxorubicin—hematologic cancer	6.67e-05	0.000176	CcSEcCtD
Avanafil—Cardiac disorder—Doxorubicin—hematologic cancer	6.62e-05	0.000175	CcSEcCtD
Avanafil—Flushing—Doxorubicin—hematologic cancer	6.62e-05	0.000175	CcSEcCtD
Avanafil—Back pain—Epirubicin—hematologic cancer	6.49e-05	0.000171	CcSEcCtD
Avanafil—Angiopathy—Doxorubicin—hematologic cancer	6.47e-05	0.000171	CcSEcCtD
Avanafil—Dizziness—Etoposide—hematologic cancer	6.46e-05	0.00017	CcSEcCtD
Avanafil—PDE5A—Hemostasis—RAC2—hematologic cancer	6.46e-05	0.00862	CbGpPWpGaD
Avanafil—Muscle spasms—Epirubicin—hematologic cancer	6.45e-05	0.00017	CcSEcCtD
Avanafil—Immune system disorder—Doxorubicin—hematologic cancer	6.45e-05	0.00017	CcSEcCtD
Avanafil—Vertigo—Methotrexate—hematologic cancer	6.45e-05	0.00017	CcSEcCtD
Avanafil—Mediastinal disorder—Doxorubicin—hematologic cancer	6.43e-05	0.00017	CcSEcCtD
Avanafil—CYP3A4—Estrogen metabolism—NQO1—hematologic cancer	6.42e-05	0.00857	CbGpPWpGaD
Avanafil—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.38e-05	0.000168	CcSEcCtD
Avanafil—Dizziness—Prednisolone—hematologic cancer	6.38e-05	0.000168	CcSEcCtD
Avanafil—Asthenia—Triamcinolone—hematologic cancer	6.36e-05	0.000168	CcSEcCtD
Avanafil—Body temperature increased—Betamethasone—hematologic cancer	6.36e-05	0.000168	CcSEcCtD
Avanafil—Body temperature increased—Dexamethasone—hematologic cancer	6.36e-05	0.000168	CcSEcCtD
Avanafil—Nausea—Cisplatin—hematologic cancer	6.34e-05	0.000167	CcSEcCtD
Avanafil—Insomnia—Prednisone—hematologic cancer	6.34e-05	0.000167	CcSEcCtD
Avanafil—Vision blurred—Epirubicin—hematologic cancer	6.33e-05	0.000167	CcSEcCtD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—hematologic cancer	6.29e-05	0.0084	CbGpPWpGaD
Avanafil—Pruritus—Triamcinolone—hematologic cancer	6.27e-05	0.000165	CcSEcCtD
Avanafil—Cough—Methotrexate—hematologic cancer	6.26e-05	0.000165	CcSEcCtD
Avanafil—Mental disorder—Doxorubicin—hematologic cancer	6.25e-05	0.000165	CcSEcCtD
Avanafil—Vomiting—Etoposide—hematologic cancer	6.22e-05	0.000164	CcSEcCtD
Avanafil—Malnutrition—Doxorubicin—hematologic cancer	6.21e-05	0.000164	CcSEcCtD
Avanafil—Agitation—Epirubicin—hematologic cancer	6.17e-05	0.000163	CcSEcCtD
Avanafil—Dyspepsia—Prednisone—hematologic cancer	6.17e-05	0.000163	CcSEcCtD
Avanafil—Rash—Etoposide—hematologic cancer	6.16e-05	0.000163	CcSEcCtD
Avanafil—Dermatitis—Etoposide—hematologic cancer	6.16e-05	0.000162	CcSEcCtD
Avanafil—Headache—Etoposide—hematologic cancer	6.12e-05	0.000161	CcSEcCtD
Avanafil—Arthralgia—Methotrexate—hematologic cancer	6.11e-05	0.000161	CcSEcCtD
Avanafil—Myalgia—Methotrexate—hematologic cancer	6.11e-05	0.000161	CcSEcCtD
Avanafil—Chest pain—Methotrexate—hematologic cancer	6.11e-05	0.000161	CcSEcCtD
Avanafil—Rash—Prednisolone—hematologic cancer	6.08e-05	0.00016	CcSEcCtD
Avanafil—Dermatitis—Prednisolone—hematologic cancer	6.07e-05	0.00016	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.07e-05	0.00016	CcSEcCtD
Avanafil—Fatigue—Prednisone—hematologic cancer	6.04e-05	0.000159	CcSEcCtD
Avanafil—Headache—Prednisolone—hematologic cancer	6.04e-05	0.000159	CcSEcCtD
Avanafil—Vertigo—Epirubicin—hematologic cancer	6.03e-05	0.000159	CcSEcCtD
Avanafil—Back pain—Doxorubicin—hematologic cancer	6.01e-05	0.000158	CcSEcCtD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—hematologic cancer	5.99e-05	0.008	CbGpPWpGaD
Avanafil—Constipation—Prednisone—hematologic cancer	5.99e-05	0.000158	CcSEcCtD
Avanafil—Muscle spasms—Doxorubicin—hematologic cancer	5.97e-05	0.000158	CcSEcCtD
Avanafil—Palpitations—Epirubicin—hematologic cancer	5.93e-05	0.000156	CcSEcCtD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—hematologic cancer	5.91e-05	0.00789	CbGpPWpGaD
Avanafil—Dizziness—Triamcinolone—hematologic cancer	5.86e-05	0.000155	CcSEcCtD
Avanafil—Cough—Epirubicin—hematologic cancer	5.86e-05	0.000155	CcSEcCtD
Avanafil—Vision blurred—Doxorubicin—hematologic cancer	5.85e-05	0.000154	CcSEcCtD
Avanafil—PDE5A—Hemostasis—SH2B3—hematologic cancer	5.85e-05	0.00781	CbGpPWpGaD
Avanafil—Infection—Methotrexate—hematologic cancer	5.82e-05	0.000153	CcSEcCtD
Avanafil—Nausea—Etoposide—hematologic cancer	5.81e-05	0.000153	CcSEcCtD
Avanafil—Hypertension—Epirubicin—hematologic cancer	5.8e-05	0.000153	CcSEcCtD
Avanafil—Asthenia—Betamethasone—hematologic cancer	5.77e-05	0.000152	CcSEcCtD
Avanafil—Asthenia—Dexamethasone—hematologic cancer	5.77e-05	0.000152	CcSEcCtD
Avanafil—Nervous system disorder—Methotrexate—hematologic cancer	5.74e-05	0.000151	CcSEcCtD
Avanafil—Nausea—Prednisolone—hematologic cancer	5.73e-05	0.000151	CcSEcCtD
Avanafil—Arthralgia—Epirubicin—hematologic cancer	5.72e-05	0.000151	CcSEcCtD
Avanafil—Chest pain—Epirubicin—hematologic cancer	5.72e-05	0.000151	CcSEcCtD
Avanafil—Myalgia—Epirubicin—hematologic cancer	5.72e-05	0.000151	CcSEcCtD
Avanafil—Agitation—Doxorubicin—hematologic cancer	5.71e-05	0.000151	CcSEcCtD
Avanafil—Pruritus—Dexamethasone—hematologic cancer	5.69e-05	0.00015	CcSEcCtD
Avanafil—Pruritus—Betamethasone—hematologic cancer	5.69e-05	0.00015	CcSEcCtD
Avanafil—Skin disorder—Methotrexate—hematologic cancer	5.69e-05	0.00015	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.68e-05	0.00015	CcSEcCtD
Avanafil—Vomiting—Triamcinolone—hematologic cancer	5.64e-05	0.000149	CcSEcCtD
Avanafil—Rash—Triamcinolone—hematologic cancer	5.59e-05	0.000147	CcSEcCtD
Avanafil—Dry mouth—Epirubicin—hematologic cancer	5.59e-05	0.000147	CcSEcCtD
Avanafil—Dermatitis—Triamcinolone—hematologic cancer	5.59e-05	0.000147	CcSEcCtD
Avanafil—PDE5A—Hemostasis—SPARC—hematologic cancer	5.58e-05	0.00745	CbGpPWpGaD
Avanafil—Vertigo—Doxorubicin—hematologic cancer	5.58e-05	0.000147	CcSEcCtD
Avanafil—Headache—Triamcinolone—hematologic cancer	5.55e-05	0.000146	CcSEcCtD
Avanafil—Body temperature increased—Prednisone—hematologic cancer	5.54e-05	0.000146	CcSEcCtD
Avanafil—Diarrhoea—Dexamethasone—hematologic cancer	5.5e-05	0.000145	CcSEcCtD
Avanafil—Diarrhoea—Betamethasone—hematologic cancer	5.5e-05	0.000145	CcSEcCtD
Avanafil—Palpitations—Doxorubicin—hematologic cancer	5.49e-05	0.000145	CcSEcCtD
Avanafil—Hypotension—Methotrexate—hematologic cancer	5.47e-05	0.000144	CcSEcCtD
Avanafil—Infection—Epirubicin—hematologic cancer	5.44e-05	0.000144	CcSEcCtD
Avanafil—Cough—Doxorubicin—hematologic cancer	5.42e-05	0.000143	CcSEcCtD
Avanafil—PDE5A—Hemostasis—LCK—hematologic cancer	5.41e-05	0.00722	CbGpPWpGaD
Avanafil—Nervous system disorder—Epirubicin—hematologic cancer	5.37e-05	0.000142	CcSEcCtD
Avanafil—Hypertension—Doxorubicin—hematologic cancer	5.36e-05	0.000141	CcSEcCtD
Avanafil—Tachycardia—Epirubicin—hematologic cancer	5.35e-05	0.000141	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.33e-05	0.000141	CcSEcCtD
Avanafil—Skin disorder—Epirubicin—hematologic cancer	5.32e-05	0.00014	CcSEcCtD
Avanafil—Dizziness—Betamethasone—hematologic cancer	5.32e-05	0.00014	CcSEcCtD
Avanafil—Dizziness—Dexamethasone—hematologic cancer	5.32e-05	0.00014	CcSEcCtD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—hematologic cancer	5.31e-05	0.00709	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—H3F3A—hematologic cancer	5.3e-05	0.00707	CbGpPWpGaD
Avanafil—Insomnia—Methotrexate—hematologic cancer	5.3e-05	0.00014	CcSEcCtD
Avanafil—Chest pain—Doxorubicin—hematologic cancer	5.29e-05	0.000139	CcSEcCtD
Avanafil—Myalgia—Doxorubicin—hematologic cancer	5.29e-05	0.000139	CcSEcCtD
Avanafil—Arthralgia—Doxorubicin—hematologic cancer	5.29e-05	0.000139	CcSEcCtD
Avanafil—Nausea—Triamcinolone—hematologic cancer	5.27e-05	0.000139	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.25e-05	0.000139	CcSEcCtD
Avanafil—PDE5A—Hemostasis—GATA3—hematologic cancer	5.25e-05	0.007	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—HSPA5—hematologic cancer	5.22e-05	0.00697	CbGpPWpGaD
Avanafil—Somnolence—Methotrexate—hematologic cancer	5.21e-05	0.000137	CcSEcCtD
Avanafil—Dry mouth—Doxorubicin—hematologic cancer	5.17e-05	0.000136	CcSEcCtD
Avanafil—Dyspepsia—Methotrexate—hematologic cancer	5.15e-05	0.000136	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PRKCZ—hematologic cancer	5.15e-05	0.00688	CbGpPWpGaD
Avanafil—Hypotension—Epirubicin—hematologic cancer	5.12e-05	0.000135	CcSEcCtD
Avanafil—Vomiting—Betamethasone—hematologic cancer	5.12e-05	0.000135	CcSEcCtD
Avanafil—Vomiting—Dexamethasone—hematologic cancer	5.12e-05	0.000135	CcSEcCtD
Avanafil—Rash—Dexamethasone—hematologic cancer	5.07e-05	0.000134	CcSEcCtD
Avanafil—Rash—Betamethasone—hematologic cancer	5.07e-05	0.000134	CcSEcCtD
Avanafil—Dermatitis—Betamethasone—hematologic cancer	5.07e-05	0.000134	CcSEcCtD
Avanafil—Dermatitis—Dexamethasone—hematologic cancer	5.07e-05	0.000134	CcSEcCtD
Avanafil—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.05e-05	0.000133	CcSEcCtD
Avanafil—Fatigue—Methotrexate—hematologic cancer	5.05e-05	0.000133	CcSEcCtD
Avanafil—Headache—Betamethasone—hematologic cancer	5.04e-05	0.000133	CcSEcCtD
Avanafil—Headache—Dexamethasone—hematologic cancer	5.04e-05	0.000133	CcSEcCtD
Avanafil—Infection—Doxorubicin—hematologic cancer	5.04e-05	0.000133	CcSEcCtD
Avanafil—Asthenia—Prednisone—hematologic cancer	5.03e-05	0.000133	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.99e-05	0.000132	CcSEcCtD
Avanafil—Nervous system disorder—Doxorubicin—hematologic cancer	4.97e-05	0.000131	CcSEcCtD
Avanafil—Pruritus—Prednisone—hematologic cancer	4.96e-05	0.000131	CcSEcCtD
Avanafil—Insomnia—Epirubicin—hematologic cancer	4.96e-05	0.000131	CcSEcCtD
Avanafil—Tachycardia—Doxorubicin—hematologic cancer	4.95e-05	0.00013	CcSEcCtD
Avanafil—Skin disorder—Doxorubicin—hematologic cancer	4.92e-05	0.00013	CcSEcCtD
Avanafil—CYP3A4—Estrogen metabolism—GSTM1—hematologic cancer	4.92e-05	0.00657	CbGpPWpGaD
Avanafil—Somnolence—Epirubicin—hematologic cancer	4.87e-05	0.000128	CcSEcCtD
Avanafil—Dyspepsia—Epirubicin—hematologic cancer	4.82e-05	0.000127	CcSEcCtD
Avanafil—PDE5A—Hemostasis—HDAC2—hematologic cancer	4.8e-05	0.00641	CbGpPWpGaD
Avanafil—Diarrhoea—Prednisone—hematologic cancer	4.79e-05	0.000126	CcSEcCtD
Avanafil—Nausea—Betamethasone—hematologic cancer	4.78e-05	0.000126	CcSEcCtD
Avanafil—Nausea—Dexamethasone—hematologic cancer	4.78e-05	0.000126	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ITGA4—hematologic cancer	4.75e-05	0.00633	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CD44—hematologic cancer	4.75e-05	0.00633	CbGpPWpGaD
Avanafil—Hypotension—Doxorubicin—hematologic cancer	4.74e-05	0.000125	CcSEcCtD
Avanafil—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.73e-05	0.000125	CcSEcCtD
Avanafil—Fatigue—Epirubicin—hematologic cancer	4.72e-05	0.000125	CcSEcCtD
Avanafil—Constipation—Epirubicin—hematologic cancer	4.69e-05	0.000124	CcSEcCtD
Avanafil—Dizziness—Prednisone—hematologic cancer	4.63e-05	0.000122	CcSEcCtD
Avanafil—Body temperature increased—Methotrexate—hematologic cancer	4.63e-05	0.000122	CcSEcCtD
Avanafil—PDE5A—Hemostasis—IL3—hematologic cancer	4.63e-05	0.00618	CbGpPWpGaD
Avanafil—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.62e-05	0.000122	CcSEcCtD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—hematologic cancer	4.62e-05	0.00616	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IFNA1—hematologic cancer	4.6e-05	0.00614	CbGpPWpGaD
Avanafil—Insomnia—Doxorubicin—hematologic cancer	4.59e-05	0.000121	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PTPN1—hematologic cancer	4.55e-05	0.00607	CbGpPWpGaD
Avanafil—Somnolence—Doxorubicin—hematologic cancer	4.51e-05	0.000119	CcSEcCtD
Avanafil—PDE5A—Hemostasis—RASGRP1—hematologic cancer	4.48e-05	0.00598	CbGpPWpGaD
Avanafil—Dyspepsia—Doxorubicin—hematologic cancer	4.46e-05	0.000118	CcSEcCtD
Avanafil—PDE5A—Hemostasis—SYK—hematologic cancer	4.46e-05	0.00596	CbGpPWpGaD
Avanafil—Vomiting—Prednisone—hematologic cancer	4.45e-05	0.000117	CcSEcCtD
Avanafil—Rash—Prednisone—hematologic cancer	4.42e-05	0.000116	CcSEcCtD
Avanafil—Dermatitis—Prednisone—hematologic cancer	4.41e-05	0.000116	CcSEcCtD
Avanafil—Headache—Prednisone—hematologic cancer	4.39e-05	0.000116	CcSEcCtD
Avanafil—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.38e-05	0.000115	CcSEcCtD
Avanafil—Fatigue—Doxorubicin—hematologic cancer	4.37e-05	0.000115	CcSEcCtD
Avanafil—Constipation—Doxorubicin—hematologic cancer	4.34e-05	0.000114	CcSEcCtD
Avanafil—Body temperature increased—Epirubicin—hematologic cancer	4.33e-05	0.000114	CcSEcCtD
Avanafil—PDE5A—Hemostasis—IFNA2—hematologic cancer	4.28e-05	0.00571	CbGpPWpGaD
Avanafil—Asthenia—Methotrexate—hematologic cancer	4.2e-05	0.000111	CcSEcCtD
Avanafil—Nausea—Prednisone—hematologic cancer	4.16e-05	0.00011	CcSEcCtD
Avanafil—Pruritus—Methotrexate—hematologic cancer	4.14e-05	0.000109	CcSEcCtD
Avanafil—PDE5A—Hemostasis—GRB2—hematologic cancer	4.03e-05	0.00537	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PDGFA—hematologic cancer	4.02e-05	0.00536	CbGpPWpGaD
Avanafil—Body temperature increased—Doxorubicin—hematologic cancer	4.01e-05	0.000106	CcSEcCtD
Avanafil—Diarrhoea—Methotrexate—hematologic cancer	4.01e-05	0.000106	CcSEcCtD
Avanafil—Asthenia—Epirubicin—hematologic cancer	3.93e-05	0.000104	CcSEcCtD
Avanafil—Pruritus—Epirubicin—hematologic cancer	3.88e-05	0.000102	CcSEcCtD
Avanafil—Dizziness—Methotrexate—hematologic cancer	3.87e-05	0.000102	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ABL1—hematologic cancer	3.87e-05	0.00516	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	3.81e-05	0.00509	CbGpPWpGaD
Avanafil—Diarrhoea—Epirubicin—hematologic cancer	3.75e-05	9.89e-05	CcSEcCtD
Avanafil—Vomiting—Methotrexate—hematologic cancer	3.72e-05	9.82e-05	CcSEcCtD
Avanafil—Rash—Methotrexate—hematologic cancer	3.69e-05	9.74e-05	CcSEcCtD
Avanafil—Dermatitis—Methotrexate—hematologic cancer	3.69e-05	9.73e-05	CcSEcCtD
Avanafil—Headache—Methotrexate—hematologic cancer	3.67e-05	9.67e-05	CcSEcCtD
Avanafil—Asthenia—Doxorubicin—hematologic cancer	3.64e-05	9.59e-05	CcSEcCtD
Avanafil—PDE5A—Hemostasis—HGF—hematologic cancer	3.64e-05	0.00486	CbGpPWpGaD
Avanafil—Dizziness—Epirubicin—hematologic cancer	3.62e-05	9.56e-05	CcSEcCtD
Avanafil—PDE5A—Hemostasis—CSF2—hematologic cancer	3.6e-05	0.0048	CbGpPWpGaD
Avanafil—Pruritus—Doxorubicin—hematologic cancer	3.59e-05	9.46e-05	CcSEcCtD
Avanafil—Vomiting—Epirubicin—hematologic cancer	3.48e-05	9.19e-05	CcSEcCtD
Avanafil—Nausea—Methotrexate—hematologic cancer	3.48e-05	9.17e-05	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PRKCG—hematologic cancer	3.47e-05	0.00463	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—JAK1—hematologic cancer	3.47e-05	0.00463	CbGpPWpGaD
Avanafil—Diarrhoea—Doxorubicin—hematologic cancer	3.47e-05	9.15e-05	CcSEcCtD
Avanafil—Rash—Epirubicin—hematologic cancer	3.45e-05	9.11e-05	CcSEcCtD
Avanafil—Dermatitis—Epirubicin—hematologic cancer	3.45e-05	9.1e-05	CcSEcCtD
Avanafil—Headache—Epirubicin—hematologic cancer	3.43e-05	9.05e-05	CcSEcCtD
Avanafil—Dizziness—Doxorubicin—hematologic cancer	3.35e-05	8.84e-05	CcSEcCtD
Avanafil—Nausea—Epirubicin—hematologic cancer	3.25e-05	8.58e-05	CcSEcCtD
Avanafil—PDE5A—Hemostasis—IL2RA—hematologic cancer	3.24e-05	0.00433	CbGpPWpGaD
Avanafil—Vomiting—Doxorubicin—hematologic cancer	3.22e-05	8.5e-05	CcSEcCtD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	3.2e-05	0.00427	CbGpPWpGaD
Avanafil—Rash—Doxorubicin—hematologic cancer	3.2e-05	8.43e-05	CcSEcCtD
Avanafil—Dermatitis—Doxorubicin—hematologic cancer	3.19e-05	8.42e-05	CcSEcCtD
Avanafil—Headache—Doxorubicin—hematologic cancer	3.18e-05	8.38e-05	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PDGFB—hematologic cancer	3.13e-05	0.00418	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—hematologic cancer	3.05e-05	0.00407	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CDK2—hematologic cancer	3.04e-05	0.00405	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	3.03e-05	0.00404	CbGpPWpGaD
Avanafil—Nausea—Doxorubicin—hematologic cancer	3.01e-05	7.94e-05	CcSEcCtD
Avanafil—PDE5A—Hemostasis—MAPK14—hematologic cancer	2.91e-05	0.00389	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—FN1—hematologic cancer	2.82e-05	0.00377	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3CG—hematologic cancer	2.7e-05	0.00361	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PTPN11—hematologic cancer	2.65e-05	0.00354	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	2.54e-05	0.00339	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	2.51e-05	0.00335	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CREBBP—hematologic cancer	2.5e-05	0.00334	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3CD—hematologic cancer	2.37e-05	0.00317	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ALB—hematologic cancer	2.34e-05	0.00313	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3R1—hematologic cancer	2.24e-05	0.00299	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—JAK2—hematologic cancer	2.18e-05	0.00291	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3CB—hematologic cancer	2.07e-05	0.00276	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IL2—hematologic cancer	1.9e-05	0.00254	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—EP300—hematologic cancer	1.71e-05	0.00228	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SRC—hematologic cancer	1.66e-05	0.00221	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	1.64e-05	0.00219	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	1.62e-05	0.00216	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VEGFA—hematologic cancer	1.62e-05	0.00216	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NRAS—hematologic cancer	1.6e-05	0.00213	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	1.54e-05	0.00206	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—MAPK3—hematologic cancer	1.53e-05	0.00204	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	1.52e-05	0.00203	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TGFB1—hematologic cancer	1.48e-05	0.00198	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—KRAS—hematologic cancer	1.37e-05	0.00183	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	1.36e-05	0.00181	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—MTR—hematologic cancer	1.34e-05	0.00178	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	1.27e-05	0.0017	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3CA—hematologic cancer	1.26e-05	0.00168	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TP53—hematologic cancer	1.22e-05	0.00163	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—HRAS—hematologic cancer	1.17e-05	0.00156	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—AKT1—hematologic cancer	1.03e-05	0.00138	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	8.8e-06	0.00118	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	8.68e-06	0.00116	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	8.09e-06	0.00108	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	7.98e-06	0.00107	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PHYH—hematologic cancer	6.75e-06	0.000901	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GMPS—hematologic cancer	6.75e-06	0.000901	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—FTCD—hematologic cancer	6.75e-06	0.000901	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SMPD3—hematologic cancer	6.17e-06	0.000824	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ASNS—hematologic cancer	5.39e-06	0.00072	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—B3GAT1—hematologic cancer	5.39e-06	0.00072	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—DCK—hematologic cancer	5.39e-06	0.00072	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HDC—hematologic cancer	5.11e-06	0.000683	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CDA—hematologic cancer	4.68e-06	0.000624	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PC—hematologic cancer	4.5e-06	0.000601	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC35B2—hematologic cancer	4.35e-06	0.00058	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GBA—hematologic cancer	4.35e-06	0.00058	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTAP—hematologic cancer	3.98e-06	0.000531	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—FHL2—hematologic cancer	3.54e-06	0.000473	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AGRN—hematologic cancer	3.48e-06	0.000464	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMMR—hematologic cancer	3.29e-06	0.00044	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—IDH2—hematologic cancer	3.29e-06	0.00044	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.1e-06	0.000414	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ACP5—hematologic cancer	3.01e-06	0.000402	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CA9—hematologic cancer	3.01e-06	0.000402	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOR2—hematologic cancer	2.97e-06	0.000397	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—IDH1—hematologic cancer	2.83e-06	0.000378	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TXN—hematologic cancer	2.8e-06	0.000374	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCC3—hematologic cancer	2.8e-06	0.000374	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTO1—hematologic cancer	2.8e-06	0.000374	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SPHK1—hematologic cancer	2.74e-06	0.000366	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.63e-06	0.000352	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.56e-06	0.000342	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.56e-06	0.000342	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.5e-06	0.000333	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NUP98—hematologic cancer	2.42e-06	0.000323	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.35e-06	0.000313	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.35e-06	0.000313	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NUP214—hematologic cancer	2.33e-06	0.000311	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.28e-06	0.000305	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTR—hematologic cancer	2.28e-06	0.000305	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ENO2—hematologic cancer	2.24e-06	0.000299	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.17e-06	0.00029	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SDC1—hematologic cancer	2.12e-06	0.000283	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NQO1—hematologic cancer	1.81e-06	0.000241	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CD44—hematologic cancer	1.81e-06	0.000241	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYCS—hematologic cancer	1.71e-06	0.000228	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.7e-06	0.000227	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.51e-06	0.000201	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.43e-06	0.00019	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.38e-06	0.000185	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.38e-06	0.000185	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.22e-06	0.000163	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.03e-06	0.000137	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.53e-07	0.000127	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CD—hematologic cancer	9.03e-07	0.000121	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALB—hematologic cancer	8.92e-07	0.000119	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.53e-07	0.000114	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CB—hematologic cancer	7.87e-07	0.000105	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTEN—hematologic cancer	6.8e-07	9.08e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—EP300—hematologic cancer	6.49e-07	8.66e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.8e-07	6.41e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AKT1—hematologic cancer	3.92e-07	5.23e-05	CbGpPWpGaD
